| Literature DB >> 34944816 |
Tobias Greve1, Liang Wang2, Sophie Katzendobler1, Lucas L Geyer3, Christian Schichor1, Jörg Christian Tonn1, Andrea Szelényi1.
Abstract
Facial muscle corticobulbar motor evoked potentials (FMcoMEPs) are used to monitor facial nerve integrity during vestibular schwannoma resections to increase maximal safe tumor resection. Established warning criteria, based on ipsilateral amplitude reduction, have the limitation that the rate of false positive alarms is high, in part because FMcoMEP changes occur on both sides, e.g., due to brain shift or pneumocephalus. We retrospectively compared the predictive value of ipsilateral-only warning criteria and actual intraoperative warnings with a novel candidate warning criterion, based on "ipsilateral versus contralateral difference in relative stimulation threshold increase, from baseline to end of resection" (BilatMT ≥ 20%), combined with an optimistic approach in which a warning would be triggered only if all facial muscles on the affected side deteriorated. We included 60 patients who underwent resection of vestibular schwannoma. The outcome variable was postoperative facial muscle function. Retrospectively applying BilatMT, with the optimistic approach, was found to have a significantly better false positive rate, which was much lower (9% at day 90) than the traditionally used ipsilateral warning criteria (>20%) and was also lower than actual intraoperative warnings. This is the first report combining the threshold method with an optimistic approach in a bilateral multi-facial muscle setup. This method could substantially reduce the rate of false positive alarms in FMcoMEP monitoring.Entities:
Keywords: cerebellopontine angle; evoked potentials; facial nerve; intraoperative; monitoring; motor; schwannoma; vestibular
Year: 2021 PMID: 34944816 PMCID: PMC8699745 DOI: 10.3390/cancers13246196
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Overview of warning criteria and outcome variables.
| Diagnostic Test | Definition | Test Negative | Test Positive |
|---|---|---|---|
| BilatMT optimistic approach | Ipsilateral versus contralateral difference in stimulation threshold increase to elicit FMcoMEPs, from baseline to the end of resection, in all ipsilateral facial muscles. | <20% | ≥20% |
| BilatMT traditional approach | Ipsilateral versus contralateral difference in stimulation threshold increase to elicit FMcoMEPs, from baseline to the end of resection, in one facial muscle. | <20% | ≥20% |
| UnilatMT optimistic approach | Increase in ipsilateral stimulation threshold necessary to elicit FMcoMEPs, from baseline to the end of resection, in all ipsilateral facial muscles. | <20 mA | ≥20 mA |
| UnilatMT traditional approach | Increase in ipsilateral stimulation threshold necessary to elicit FMcoMEPs, from baseline to the end of resection, in one ipsilateral facial muscle. | <20 mA | ≥20 mA |
| Intraoperative warningto the surgeon |
Prolonged A-train activity. Amplitude reduction >50% which required increase in stimulation intensity. Transient FMcoMEP loss. Permanent FMcoMEP loss. | No intraoperative warning | Intraoperative warning issued |
FMcoMEP—facial muscle corticobulbar motor evoked potential; DNS—direct nerve stimulation.
Patient characteristics.
| Variables | Value |
|---|---|
| Patients, | 60 |
| Procedures, | 61 |
| Sex, female | 26 (43%) |
| Age, years | 51.5 ± 13.4 (range 21.4–83.5 years) |
| Tumor volume, cm3 | 19.5 ± 21.4 cm3 (range 1.4–113 mL) |
| Hannover Grading | |
| T1 | 0 |
| T2 | 1 (1.6%) |
| T3a | 11 (18.0%) |
| T3b | 17 (27.9%) |
| T4a | 20 (32.8%) |
| T4b | 12 (19.7%) |
| Extent of resection | |
| Gross total resection | 48 (78.7%) |
| Near total resection | 12 (19.7%) |
| Partial resection | 1 (1.6%) |
Sex, Hannover grading, and extent of resection are noted as count and frequency. Age and tumor volume are noted as mean ± standard deviation.
Figure 1Time plot of facial muscle function. Absolute number of House–Brackmann (HB) scores at each time point are listed inside each bar.
Patient data.
| Facial Function | Outcome Measure | Ipsilateral Stimulation Threshold Increase to Elicit FMcoMEPs (mA) | Ipsilateral versus Contralateral Difference in Stimulation | Intraoperative Warnings | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Identifier | Tumor volume [mL] | Hanover grading | Extent of resection | Preoperatively | Day 1 | Day 7 | Day 90 | Day 1 | Day 7 | Day 90 | Oculi | Oris | Mentalis | Optimistic | Traditional | Oculi | Oris | Mentalis | Optimistic | Traditional | |
| 1 | 19 | 5 | NTR | 1 | 2 | 3 | 2 | 0 | 0 | 0 | 9 | 4 | 9 | 4 | 9 | 9 | 4 | 9 | 4 | 9 | |
| 2 | 18 | 6 | GTR | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 12 | 9 | 9 | 12 | 17 | 13 | 13 | 17 | |||
| 3 | 3 | 4 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 13 | 9 | 9 | 13 | 14 | 9 | 9 | 14 | AT | ||
| 4 | 4 | 3 | GTR | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | |||||||||
| 5 | 7 | 5 | GTR | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | |||
| 6 | 30 | 5 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 10 | 8 | |||||||||
| 7 | 7 | 5 | GTR | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 12 | 12 | 12 | 12 | 9 | 9 | 9 | 9 | |||
| 8 | 33 | 5 | GTR | 1 | 4 | 4 | 1 |
|
| 0 |
|
|
|
|
|
|
|
|
|
| STIM |
| 9 | 12 | 4 | GTR | 1 | 4 | 3 | 2 |
| 0 | 0 |
|
|
|
|
|
|
|
|
|
| STIM |
| 10 | 88 | 6 | PR | 1 | 5 | 4 | 4 |
|
|
|
|
|
|
|
|
|
|
|
|
| LOSS perm |
| 11 | 8 | 4 | GTR | 1 | 6 | 6 | 5 |
|
|
|
|
|
|
|
|
|
|
|
|
| FLUC |
| 12 | 31 | 6 | NTR | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 9 | 7 | |||||||||
| 13 | 56 | 6 | GTR | 1 | 3 | 3 | 1 | 0 | 0 | 0 | 17 | 17 | 14 | 14 | 17 |
|
| 10 | 10 |
| FLUC |
| 14 | 2 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 |
| 2 |
| 2 |
| STIM | ||
| 15 | 6 | 4 | GTR | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 10 | 10 | 10 | 10 | |||
| 16 | 4 | 4 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 7 | 7 | |||
| 17 | 10 | 5 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 7 | 7 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | AT |
| 18 | 2 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | |
| 19-1 | 19 | 6 | GTR | 1 | 2 | 2 | 2 | 0 | 0 | 0 |
| 18 | 18 | 18 |
| 13 | 2 | 2 | 2 | 13 | AT |
| 20 | 4 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | |||
| 21 | 43 | 6 | GTR | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 11 | 11 | 11 | 11 | 0 | 0 | 0 | 0 | |||
| 22 | 12 | 4 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 10 | 2 | 10 | 0 | 8 | 0 | 8 | |||
| 23 | 113 | 6 | NTR | 1 | 3 | 2 | 1 | 0 | 0 | 0 |
| 17 | 17 |
|
| 14 | 14 |
| STIM | ||
| 24 | 5 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 6 | 7 | 6 | 6 | 7 | 7 | 8 | 7 | 7 | 8 | |
| 25 | 3 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 10 | 1 | 10 | 0 | 0 | 0 | 0 | |||
| 26 | 4 | 4 | GTR | 1 | 2 | 2 | 1 | 0 | 0 | 0 |
| 0 | STIM | ||||||||
| 27 | 6 | 4 | GTR | 1 | 3 | 3 | 1 | 0 | 0 | 0 | 16 | 17 | 16 | 17 | 0 | 0 | 0 | 0 | |||
| 28 | 35 | 6 | NTR | 1 | 2 | 2 | 2 | 0 | 0 | 0 |
|
|
|
|
| 4 | 3 | 4 | 3 | 4 | STIM |
| 29 | 8 | 2 | GTR | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 30 | 30 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 31 | 43 | 6 | NTR | 2 | 3 | 2 | 2 | 0 | 0 | 0 | 18 | 0 | 0 | 18 | 0 | 0 | 0 | 0 | |||
| 32 | 15 | 5 | NTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
|
|
|
|
| 0 | 0 |
| STIM | ||
| 33 | 26 | 5 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 3 | 0 | |||||||||
| 34 | 34 | 5 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 3 | 4 | 3 | 4 | 2 | 3 | 2 | 3 | |||
| 35 | 35 | 5 | GTR | 2 | 3 | 2 | 2 | 0 | 0 | 0 |
| 14 | STIM | ||||||||
| 36 | 40 | 6 | NTR | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 9 | 0 | |||||||||
| 37 | 1 | 3 | GTR | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 9 | 11 | 9 | 11 | 0 | 0 | 0 | 0 | |||
| 38 | 43 | 6 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 4 |
|
| 4 |
| 6 |
|
| 6 |
| STIM |
| 39 | 2 | 3 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| 1 | 0 |
| 0 | 0 | 0 | 0 | 0 | STIM |
| 40 | 18 | 5 | NTR | 1 | 4 | 3 | 1 |
| 0 | 0 | 17 |
| |||||||||
| 41 | 12 | 5 | GTR | 1 | 3 | 3 | 1 | 0 | 0 | 0 |
|
|
|
|
|
|
|
|
|
| STIM |
| 42 | 19 | 5 | GTR | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 2 |
| |||||||||
| 43 | 15 | 5 | GTR | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 8 |
| 8 |
| 9 |
| 9 |
| LOSS trans | ||
| 44 | 12 | 3 | GTR | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 45 | 7 | 4 | GTR | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 46 | 17 | 4 | GTR | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 47 | 11 | 5 | GTR | 1 | 2 | 2 | 1 | 0 | 0 | 0 |
|
|
|
| 19 | 0 | 0 | 19 | STIM | ||
| 19-2 | 3 | 3 | GTR | 1 | 3 | 3 | 1 | 0 | 0 | 0 |
|
|
|
| 0 | 12 | 0 | 12 | STIM | ||
| 48 | 2 | 4 | GTR | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 18 |
| 18 |
| 0 | 0 | 0 | 0 | STIM | ||
| 49 | 13 | 5 | GTR | 1 | 1 | 1 | 3 | 0 | 0 | 0 |
|
|
|
| 0 | 0 | 0 | 0 | STIM | ||
| 50 | 4 | 4 | GTR | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | |
| 51 | 7 | 4 | NTR | 1 | 3 | 3 | 1 | 0 | 0 | 0 |
| 0 | FLUC | ||||||||
| 52 | 19 | 5 | NTR | 1 | 4 | 4 | 3 |
|
| 0 |
|
|
|
|
|
|
|
| FLUC + AT | ||
| 53 | 5 | 4 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 9 | 8 | |||||||||
| 54 | 7 | 4 | GTR | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 55 | 78 | 6 | NTR | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 14 | 14 | 14 | 14 | 17 | 17 | 17 | 17 | |||
| 56 | 13 | 5 | NTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
|
|
|
| 4 |
| 4 |
| FLUC | ||
| 57 | 12 | 5 | GTR | 1 | 2 | 2 | 1 | 0 | 0 | 0 |
|
|
|
| 0 |
| 0 |
| STIM | ||
| 58 | 10 | 4 | GTR | 3 | 3 | 3 | 2 | 0 | 0 | 0 | 14 | 16 | 14 | 16 | 13 | 14 | 13 | 14 | LOSS trans | ||
| 59 | 34 | 5 | GTR | 4 | 3 | 2 | 1 | 0 | 0 | 0 |
| 15 | 15 |
|
| 0 | 0 |
| STIM | ||
| 60 | 8 | 4 | GTR | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| 19 |
| 19 |
| 0 | 0 | 0 | 0 | 0 | STIM |
Cells are marked in bold if any of the diagnostic criteria exceeded the predefined hazard limit or, in case of the outcome measure, if facial function showed relevant deterioration. Outcome measure: dichotomized between 0 = no/mild deterioration (increase/no increase in House–Brackmann score, but absolute value ≤3) and 1 = relevant deterioration (increase in House–Brackmann score, absolute value ≥4); AT—warning due to A-train activity; STIM—warning due to amplitude reduction >50% that obligated us to increase stimulation intensity; LOSS perm—warning due to permanent loss of FMcoMEPs; LOSS trans—warning due to transient loss of FMcoMEPs; FLUC—warning due to amplitude fluctuations.
Figure 2Correlation and ROC curve analysis (A) Correlation between change in ipsilateral versus contralateral difference in stimulation threshold increase to elicit FMcoMEPs (BilatMT) and absolute House–Brackmann (HB) score. The correlation was significant for all three time points. (B) Comparison of two forms of dichotomization for outcome measurement, for both BilatMT and ipsilateral stimulation threshold increase (UnilatMT). The area under the curve (AUC) was significantly higher for all time points for both BilatMT and UnilatMT.
Figure 3Exemplary IOM data and calculation of warning criteria of patient 11. (A) Baseline and final FMcoMEP measurements of the mentalis muscle on the ipsilateral and contralateral sides are shown. For each potential, the amplitude and stimulation intensity are measured. (B) Exemplary calculation. The upper calculation refers to the UnilatMT criterion and is calculated by subtracting the baseline from the final stimulation threshold. In this case, the UnilatMT criterion is met because the ipsilateral versus contralateral difference is 59 mA, which is above the 20 mA hazard limit. The bottom calculation refers to the BilatMT criterion and is calculated by subtracting the relative ipsilateral from the relative contralateral increase. In this case, the BilatMT criterion is met because the relative difference is 30%, which is above the 20% hazard limit.
Risk stratification.
| Criterion | Time Point | Orbicularis Oculi Muscle | Orbicularis Oris Muscle | Mentalis Muscle | Optimistic Approach | Traditional Approach |
|---|---|---|---|---|---|---|
| Sensitivity, specificity in % | ||||||
| BilatMT | Day 1 | 100, 87 | 100, 85 | 100, 87 |
| 100, 76 |
| Day 7 | 100, 81 | 100, 82 | 100, 85 |
| 100, 74 | |
| Day 90 | 100, 76 | 100, 79 | 100, 81 |
| 100, 70 | |
| UnilatMT | Day 1 | 100, 73 | 83, 69 | 100, 71 | 100, 80 | 100, 59 |
| Day 7 | 100, 69 | 100, 68 | 100, 70 | 100, 79 | 100, 57 | |
| Day 90 | 100, 65 | 100, 65 | 100, 67 | 100, 75 | 100, 55 | |
| Intraoperative warnings | Day 1 | 83, 56 | ||||
| Day 7 | 100, 56 | |||||
| Day 90 | 100, 54 | |||||
| Positive predictive value, negative predictive value in % | ||||||
| BilatMT | Day 1 | 45, 100 | 43, 100 | 45, 100 |
| 31, 100 |
| Day 7 | 27, 100 | 28, 100 | 32, 100 |
| 21, 100 | |
| Day 90 | 13, 100 | 14, 100 | 15, 100 |
| 10, 100 | |
| UnilatMT | Day 1 | 29, 100 | 23, 97 | 27, 100 | 36, 100 | 21, 100 |
| Day 7 | 18, 100 | 18, 100 | 19, 100 | 25, 100 | 14, 100 | |
| Day 90 | 9, 100 | 9, 100 | 9, 100 | 12, 100 | 7, 100 | |
| Intraoperative warnings | Day 1 | 6, 99 | ||||
| Day 7 | 7, 100 | |||||
| Day 90 | 7, 100 | |||||
| False negative rate, false positive rate in % | ||||||
| BilatMT | Day 1 | 0, 13 | 0, 15 | 0, 13 |
| 0, 24 |
| Day 7 | 0, 19 | 0, 18 | 0, 15 |
| 0, 26 | |
| Day 90 | 0, 24 | 0, 21 | 0, 19 |
| 0, 30 | |
| UnilatMT | Day 1 | 0, 27 | 17, 31 | 0, 29 | 0, 20 | 0, 41 |
| Day 7 | 0, 31 | 0, 32 | 0, 30 | 0, 21 | 0, 43 | |
| Day 90 | 0, 35 | 0, 35 | 0, 33 | 0, 25 | 0, 45 | |
| Intraoperative warnings | Day 1 | 17, 44 | ||||
| Day 7 | 0, 44 | |||||
| Day 90 | 0, 46 | |||||
The values in bold indicate the condition with the best results.